STEANN PHARMA
ActiveSummary
STEANN PHARMA has been active since 2016 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €777,026 and a net result of €46,556. Equity is growing by about 17% per year across the filed financial years. Its solvency ranks better than 39% of 10,760 sector peers (NACE 70, financial year 2025). The computed 12-month bankruptcy probability is 0.2% (very low).
History
Acts, filings and financial milestones
19-01
Gazette deed
Resignation: A.N.W.- SOFT BV (director)Permanent representative: DE SWERT Anneleen · Appointment: DE SWERT Anneleen (director) · Registered-office move16 facts ▸
- General meeting, 21-12-2023
- Registered-office move, Vlaamse Gewest
- Amendment of the articles (2 times)
- Other provision, “van rechtswege, in regel brengen met Wetboek van Vennootschappen en Verenigingen” (deed in Dutch)
- Legal-form conversion, “besloten vennootschap” (deed in Dutch)
- Capital conversion, “statutair onbeschikbare eigen vermogensrekening” (deed in Dutch)
- Reserve release, “statutair onbeschikbare eigen vermogensrekening, beschikbaar stellen” (deed in Dutch)
- Capital
- Power of attorney, Jan Verreth
- Director resignation, A.N.W.- SOFT BV (director)
- Other provision, “raadpleging Register Bestuursverboden, zonder resultaat” (deed in Dutch)
- Other provision, “verklaring afwezigheid bestuursverbod, geen strafrechtelijk noch civielrechtelijk verbod van toepassing” (deed in Dutch)
- +4 further facts in this act
About the unread acts
Of the 3 Belgian Official Gazette deeds we know for this company, 1 has been read. The other 2 have not been read yet: what they contain is neither established nor disproved here.